The proof-of-concept trial in hepatitis C virus (HCV)-infected patients is being conducted at multiple centers around the world. The trial design is a Phase I/II, double-blind, placebo-controlled, dose-escalation
Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute and service Base technology products developed by Oxford Nanopore for DNA sequencing into the research
The Vu e-POD and Vu L-POD received clearance from the FDA to be marketed as a spinal intervertebral body fusion device (IBD). Prior to receiving the IBD status,
The Phase II trial involves treatment of patients with advanced, primary liver cancer refractory to standard therapies. Patients are randomized to receive treatment at one of two dose
The Phase II clinical trial, which began at the end of December 2008, is designed as a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability
The three new brands are Pacnex wash, a topical treatment for acne; Sumaxin cleansing pads, a topical treatment for acne, rosacea and seborrheic dermatitis; and Uramaxin nail gel,
The acquisition has been approved by Ablation Frontiers’s shareholders, and is subject to regulatory clearance. The transaction is expected to close in Medtronic’s fourth fiscal quarter, ending April
Under the terms of the agreement, Bayer Schering Pharma will pay Micromet a E4.5 million fee to secure a one year option on a specific BiTE antibody. Bayer
The trial will evaluate the efficacy of PRX302 versus placebo using the optimal treatment volume established in the open-label Phase II study results announced in November, 2008. The
Under the terms of the merger agreement, Targanta shareholders will receive $2 in cash up front for each common share tendered, or approximately $42 million. Targanta shareholders may
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.